Key points are not available for this paper at this time.
To the editor: Lonial and Gertz raise important concerns about the definition of disease progression used in patients who are in complete response following therapy for myeloma.11 They also correctly highlight the limitation of using immunofixation to categorize complete response (CR), and call
Rajkumar et al. (2008) studied this question.